Stay updated with breaking news from Nasdaq Blph. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) saw a large drop in short interest in the month of April. As of April 15th, there was short interest totalling 434,800 shares, a drop of 22.3% from the March 31st total of 559,800 shares. Based on an average daily trading volume, of 1,190,000 shares, the short-interest ratio […]
Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) was upgraded by StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday. Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 target price on shares of Bellerophon Therapeutics in a research report on Tuesday, April 4th. […]
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) was the recipient of a large drop in short interest in March. As of March 31st, there was short interest totalling 559,800 shares, a drop of 40.8% from the March 15th total of 945,100 shares. Based on an average trading volume of 1,210,000 shares, the days-to-cover ratio is […]
Bellerophon Therapeutics, Inc. (NASDAQ:BLPH – Get Rating) – HC Wainwright issued their Q1 2023 earnings per share estimates for Bellerophon Therapeutics in a report released on Tuesday, April 4th. HC Wainwright analyst A. Fein forecasts that the biotechnology company will post earnings of ($0.47) per share for the quarter. HC Wainwright currently has a “Buy” […]
StockNews.com assumed coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH – Get Rating) in a report published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Bellerophon Therapeutics Stock Up 5.8 % Shares of NASDAQ BLPH opened at $7.89 on Wednesday. The company has a market cap of $76.77 million, a P/E […]